|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
PUBLIC RELEASE DATE:
14-Dec-2014
Contact: Alan Gill
[email protected]
61-393-452-719
Walter and Eliza Hall Institute
@WEHI_research
Potential cure for hepatitis B enters phase 1/2a clinical trial
IMAGE: Dr Marc Pellegrini (L), Dr Greg Ebert and colleagues have developed a new treatment for chronic hepatitis B infections that is entering clinical trials.
Click here for more information.
A new treatment developed by Walter and Eliza Hall Institute researchers to promote the cure of chronic hepatitis B virus (HBV) infection is now recruiting patients for a phase I/2a clinical trial.
Dr Marc Pellegrini, Dr Greg Ebert and colleagues developed the new treatment in collaboration with TetraLogic Pharmaceuticals, a biotech company based in Malvern, Pennsylvania, US. The clinical trial will be held at sites across Australia and New Zealand, including Melbourne, Adelaide, Perth and Auckland.
Hepatitis B is a viral disease that infects liver cells. Although a vaccine has been available since 1982, more than two billion people worldwide are infected with the virus. Most patients will recover from the disease, but 5-10 per cent of patients will develop a chronic infection, with children most at risk. More than 780,000 people die every year from complications associated with chronic hepatitis B infection, including cirrhosis and liver cancer.
The new treatment uses TetraLogic Pharmaceutical's drug birinapant, which triggers the breakdown of proteins that prevent infected cells from self-destructing. Dr Pellegrini said these proteins, known as 'inhibitors of apoptosis proteins' (IAPs), can be targeted to allow infected cells to die.
"Our preclinical models have shown that birinapant kills infected liver cells, while not harming uninfected cells," he said. "Used in conjunction with an existing treatment for hepatitis B, this drug has the potential, for the first time, to functionally cure chronic hepatitis B infections."
Dr Pellegrini said the new treatment had the potential to revolutionise the way chronic HBV infections were treated. "Patients who develop chronic infections can be treated with drugs that prevent the virus from replicating, reducing the amount of virus in the liver, but do not completely eliminate the virus," he said. "These patients are dependent on anti-viral drugs that need to be taken for a very long period of time to reduce the risk of virus-induced liver damage and the complications that come with it.
"Our new therapy combines an existing anti-viral drug, which reduces the viral load, with birinapant that promotes efficient killing of hepatitis B infected cells and clearance of the virus from the system."
"We are really excited that this treatment has entered phase 1/2a clinical trials as it is a culmination of many years work in developing new strategies to tackle chronic infections."
Based on his crucial research, Dr Pellegrini is the key scientific and clinical advisor for the clinical study that is now underway. The study is sponsored by TetraLogic Pharmaceuticals Corporation in collaboration with Nucleus Network in Melbourne and hospitals across Australia and New Zealand.
###
The phase 1/2a clinical trial will involve approximately 50 patients and is currently recruiting eligible participants. For more information about the trial and eligibility, contact Nucleus Network at [email protected].
公开发布日期：
12月14日 - 2014年
联系方式：阿伦·吉尔
[email protected]
61-393-452-719
沃尔特伊丽莎研究所大厅
@WEHI_research
潜在的治愈乙肝进入阶段1/ 2A临床试验
IMAGE：马克·佩莱格里尼博士（L），格雷格博士艾伯特和他的同事已经开发正在进入临床试验的慢性乙肝感染的新疗法。
请点击这里获取更多信息。
由沃尔特伊丽莎馆研究所的研究人员开发，促进慢性乙型肝炎病毒（HBV）感染的治疗的新疗法正在招募患者的阶段I /2A临床试验。
医生马克·佩莱格里尼，格雷格·艾伯特博士和他的同事开发出符合TetraLogic制药，总部设在宾夕法尼亚州Malvern，美国一家生物科技公司合作的新的治疗方法。临床试验将在澳大利亚和新西兰的网站，包括墨尔本，阿德莱德，珀斯和奥克兰举行。
乙型肝炎是一种病毒疾病，感染肝细胞。虽然疫苗自1982年以来一直使用，两个以上的十亿人都在全球感染了病毒。大多数患者从疾病中恢复过来，但患者5％-10％会发展为慢性感染，与孩子们最危险的。超过78万人，每年死于慢性乙肝感染，包括肝硬化和肝癌相关的并发症。
新治疗用途TetraLogic药典的药物birinapant，这触发蛋白质防止感染的细胞从自毁的破裂。佩莱格里尼博士说，这些蛋白质，称为（单边行动计划）“凋亡蛋白抑制剂”，可以有针对性地使被感染的细胞死亡。
“我们的临床前模型显示，birinapant杀死被感染的肝细胞，而不会伤及未受感染的细胞，”他说。 “用于结合为乙型肝炎现有治疗，这种药物有潜力，对于第一次，在功能上治愈慢性乙型肝炎感染。”
佩莱格里尼博士说，新的治疗必须彻底改变的慢性HBV感染的治疗方式的潜力。 “谁的患者发展为慢性感染可以用药物防止病毒复制，减轻肝脏中病毒的数量，但并不能完全消除病毒治疗，”他说。 “这些患者都依赖于抗病毒的药物，需要采取了很长的一段时间，以减少病毒诱导的肝损伤的风险和随之而来的并发症。
“我们的新疗法结合了现有的抗病毒的药物，从而降低了病毒载量，以birinapant促进高效杀灭乙型肝炎感染的细胞，并从该系统中的病毒的清除。”
“我们非常高兴，这种治疗已进入阶段1 /2A临床试验，因为它是多年工作在开发新战略以应对慢性感染的高潮。”
根据他的研究非常重要，佩莱格里尼医生是关键的科学和临床顾问的临床研究，目前正在进行中。这项研究是由TetraLogic制药公司与中核网在墨尔本和在澳大利亚和新西兰的医院合作举办。
###
阶段1/ 2A临床试验将涉及大约50名患者，目前正在招募符合条件的参与者。有关试验和资格的更多信息，请联系网络核心在[email protected]。
|
|
楼主: newchinabok
发表于 2014-12-11 16:32
